{"disease":{"id":"bladder-urothelial-carcinoma","name":"bladder urothelial carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06167356","title":"Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT07395037","title":"A Study of Ward Admissions for Haematuria","phase":"","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"British Urology Researchers in Surgical Training","has_results":false},{"nct_id":"NCT03091660","title":"S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT05987241","title":"Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":992,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03244384","title":"Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":739,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05092958","title":"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":654,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00942331","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":506,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04617743","title":"The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Istanbul Medeniyet University","has_results":false},{"nct_id":"NCT07097142","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":486,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT05337189","title":"A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China","phase":"","overall_status":"RECRUITING","enrollment_count":482,"lead_sponsor_name":"Creative Biosciences (Guangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT03775265","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":475,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06193941","title":"Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT04647981","title":"Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test.","phase":"","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"Clinique Beau Soleil","has_results":false},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04129606","title":"Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Abdelwahab Hashem","has_results":false},{"nct_id":"NCT07037589","title":"Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT04688931","title":"A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":282,"lead_sponsor_name":"UroGen Pharma Ltd.","has_results":true},{"nct_id":"NCT03606174","title":"A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":260,"lead_sponsor_name":"Mirati Therapeutics Inc.","has_results":true},{"nct_id":"NCT06129084","title":"A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"Bernie Eigl","has_results":false},{"nct_id":"NCT03609216","title":"Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":237,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT03584659","title":"Patient-reported Outcomes in Bladder Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04770974","title":"Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University of Florence","has_results":false},{"nct_id":"NCT05220124","title":"A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":190,"lead_sponsor_name":"Tianjin Medical University Second Hospital","has_results":false},{"nct_id":"NCT04579224","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06138561","title":"Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments","phase":"","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT07322263","title":"Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Michael A. O'Donnell","has_results":false},{"nct_id":"NCT02844816","title":"Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":172,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06020807","title":"Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Nucleix Ltd.","has_results":false},{"nct_id":"NCT06416319","title":"Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct)","phase":"NA","overall_status":"RECRUITING","enrollment_count":164,"lead_sponsor_name":"Universitätsmedizin Mannheim","has_results":false},{"nct_id":"NCT04164082","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":161,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06770582","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02951325","title":"Bladder Cancer Adjuvant Radiotherapy Trial","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":153,"lead_sponsor_name":"Tata Memorial Centre","has_results":false},{"nct_id":"NCT02496208","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":152,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07589413","title":"Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Zhiping Wang","has_results":false},{"nct_id":"NCT05699135","title":"A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer","phase":"","overall_status":"TERMINATED","enrollment_count":150,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04579133","title":"Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":140,"lead_sponsor_name":"Latin American Cooperative Oncology Group","has_results":false},{"nct_id":"NCT03329950","title":"A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT00365157","title":"Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":132,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07225205","title":"Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy","phase":"NA","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT06040762","title":"A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT07061964","title":"Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":111,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02717156","title":"Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":103,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT07302230","title":"Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT07029256","title":"Ultrasound-Guided Core Needle Biopsy to Stage Urothelial Carcinoma of the Bladder (US UCB)","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03333616","title":"Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03138824","title":"Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT05335512","title":"Intravesical BCG: is the Urinary Bladder Ready to Receive it","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Tata Memorial Centre","has_results":false},{"nct_id":"NCT03397394","title":"Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":97,"lead_sponsor_name":"pharmaand GmbH","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}